• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

How Accurate and Actionable?





Lifelink (depending upon data source) will tend to exaggerate dynamic RXs (by dynamic I mean those where a change has occurred, new, switch, add etc.). This occurs because to get ideal data you need a 100% pharmacy panel with no gaps or omissions and perfect matching of patients between pharmacies/data sources.

In reality you will have gaps and inconsistencies which means you see individual RXs in locations with no history or following RXs (i.e. a single Rx). The system will label these as 'New' and hence put it in the 'New to Brand' basket. However this could be a patient who has been on the same drug every month, but normally takes there prescriptions to a different (non-panel) pharmacy and on this occasion happened to do something different. Hence what is really a repeat RX appears dynamic.

As a general rule, metrics like NTB are useful to track, but best used as a relative and directional measure (i.e. is it going up or staying the same) rather than as an absolute figure.

Similar caution should be exercised with any compliance/persistence/adherence studies measured from this data source, since it will suffer from the same problem - patients appearing to be missing RXs when they go elsewhere, and lots of short durations of treatment.